Warsaw-based Holi secures €680k in pre-seed round funding. It was run by YZR Capital, a German fund that specialised in health technology. Along with business angels Damian Zapłata (CEO of Modivo and former Allegro board member) and Robert Bogucki (co-founder of deepsense.ai and Codilime), the Berlin-based HEARTFELT_ was also involved in the round.
Read also – UK-based Accenture Acquire 6point6
With the funds that have been raised, Holi will carry out its objective of promoting a comprehensive strategy for metabolic health by expanding its product line, entering new markets, and developing proprietary technology.
Paweł Seweryn, Co-founder of Holi said, “Prevention is the medicine of the future. We are building a scalable solution thanks to our specialization in chronic metabolic disease, which increases the risk of premature death from 20 up to 100%. We connect diet, medicine and lifestyle, focusing on aspects such as changing eating habits, regulating sleep, daily physical activity and drug treatment precisely tailored to the patient. We fuel the business with technology, health biomarker analytics and proprietary methodology created by leading Polish doctors,”.
Henric Hungerhoff, General Partner at HEARTFELT said, “It is estimated that more than 200 million adults suffer from chronic metabolic diseases in the European Union alone. These are frightening figures, but observing the growing trend of healthy living, we firmly believe that awareness of metabolic health will increase significantly in the near future. Holi contributes to this,Thanks to Holi’s specialization, I see a very large room for scaling the business adhering to the tech-enabled clinic approach, which was an important element for us when deciding to invest,”.
With the application of cutting-edge therapies, Holi’s methodology transforms the way obesity is treated through the development of a personalised eating plan that aims to help patients reach mutually agreed-upon goals with their nutritionist and practitioner.
Markus Feuerecker, Founding Partner at YZR Capital said, “The European market lacks companies that focus on changing individual patients’ habits to improve metabolic health, which may potentially include the safe implementation of GLP-1 agonists as one of the many pieces of the puzzle. The Holi methodology is exceptional in this regard, When I first met Pawel and Mikolaj, they impressed me with their vision and enthusiasm. They have proven over the past years that they are capable of successfully executing their business ventures, so we are excited to support them on their mission to change the metabolic health market.”
Beginning with a holistic health programme designed to combat obesity, the Polish company was founded in early 2023 by Mikolaj Szymanski, the creator of the KERRIS group, and Pawel Seweryn, the former CEO of Daftcode. In addition to being a technological startup, Holi is a recognised medical entity.